New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide

W. Boxtel, Ben Bulten, A.M. Mavinkurve-Groothuis, L. Bellersen, C.M. Mandigers, L.A. Joosten, L. Kapusta, Lioe-Fee de Geus-Oei, H.W. van Laarhoven

Research output: Contribution to journalArticleAcademicpeer-review

41 Citations (Scopus)
3 Downloads (Pure)


Objective: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Methods: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. Results: 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = −0.564, p ≤ 0.01). Conclusion: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
Original languageEnglish
Pages (from-to)143-148
Number of pages6
Issue number2
Publication statusPublished - 2015

Cite this